KYMAB
LIVE

Serial Number

88441516

Owner

Kymab Limited

Attorney

Mark H. Tidman

Filing Date

May 22, 2019

Add to watchlist:

No watchlists yet
View on USPTO

KYMAB Trademark

Serial Number: 88441516 • Registration: 6473731

KYMAB is a trademark filed by Kymab Limited on May 22, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Kymab Limited (9 trademarks)

Babraham Research Campus
Cambridge CB22 3AT , GB

Entity Type: 99

Trademark Details

Filing Date

May 22, 2019

Registration Date

September 7, 2021

Published for Opposition

March 23, 2021

Goods & Services

Pharmaceutical and medical preparations containing monoclonal antibodies for the treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; Veterinary preparations containing monoclonal antibodies for treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, autoimmune and infectious diseases, and medical diagnostics; sanitary preparations containing monoclonal antibodies for medical purposes; dietetic food and beverages containing monoclonal antibodies, for medical and veterinary use; dietary supplements containing monoclonal antibodies for human beings and animals; dietary supplements containing monoclonal antibodies; Pharmaceutical preparations containing monoclonal antibodies for the treatment of treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases and in the field of antibodies and immuno-oncology

Medical services; diagnostic and prognostic medical services; veterinary services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pharmaceutical consultation in the nature of pharmacy advice; medical and health services in the nature of the treatment and prophylaxis of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics; Medical screening

Scientific, medical and technological services, namely, scientific research, analysis and testing in the field of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology, and scientific research, analysis and testing in the field of antibodies and cell repertoires and research, development and design in the field of science, medicine, and technology; industrial analysis and industrial research services, namely, testing, analysis, and evaluation of the goods of others to assure compliance with industry standards; design and development of computer hardware and software; design and development of hardware and software for analysis and testing in the field of antibodies and biological cells and genetic discovery and clinical development; Clinical research in the field of medical conditions in humans, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodies, immuno-oncology, inflammation, haematology and infectious disease; Conducting clinical trials for others in the field of antibodies, and medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; conducting clinical trials for pharmaceutical products for others in the field of medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; scientific and medical screening and assaying of medical conditions, namely, cancer, inflammatory, hematology, autoimmune and infectious diseases, and medical diagnostics, and in the field of antibodies and immuno-oncology; scientific and medical screening and assaying in the field of genetic discovery, clinical development, antibodies and biological cells; chemical analysis; chemical research

Filing History

REGISTERED-PRINCIPAL REGISTER
Sep 7, 2021 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Aug 1, 2021 ETOP
EXTENSION OF TIME TO OPPOSE RECEIVED
Apr 21, 2021 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 23, 2021 NPUB
PUBLISHED FOR OPPOSITION
Mar 23, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 3, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 17, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 17, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 17, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 17, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 17, 2021 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 9, 2020 GNRN
NON-FINAL ACTION E-MAILED
Oct 9, 2020 GNRT
NON-FINAL ACTION WRITTEN
Oct 9, 2020 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 22, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 21, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 21, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 16, 2020 GNRN
NON-FINAL ACTION E-MAILED
Mar 16, 2020 GNRT
NON-FINAL ACTION WRITTEN
Mar 16, 2020 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Mar 9, 2020 ZZZX
ELECTRONIC RECORD REVIEW COMPLETE
Feb 21, 2020 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Feb 21, 2020 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 14, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 14, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 14, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 14, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 14, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 29, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 28, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 28, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 9, 2019 GNRN
NON-FINAL ACTION E-MAILED
Aug 9, 2019 GNRT
NON-FINAL ACTION WRITTEN
Aug 9, 2019 CNRT
ASSIGNED TO EXAMINER
Aug 9, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 6, 2019 NWOS
NEW APPLICATION ENTERED
May 25, 2019 NWAP